Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) was founded in 2001 and is headquartered in Charlottesville, Virginia, USA, with 10 full-time employees. It is a clinical-stage biopharmaceutical company that develops treatments for cancer.
Diffusion Pharmaceuticals (DFFN):
Diffusion Pharmaceuticals Inc. is a publicly listed biotechnology and drug development company headquartered in Charlottesville, Virginia, USA. It was founded in 2001 by American life science entrepreneur David Kalergis and University of Virginia chemical engineering professor John L. Gainer.
Gainer is the inventor of Diffusion Pharmaceuticals’ oxygen diffusion enhancing compound platform technology and its leading drug, sodium trans-crocetin (TSC). The role of TSC is to increase the speed at which oxygen moves through plasma through a diffusion process, a phenomenon that forms the basis of the company’s name.
TSC and other oxygen-diffusing compounds, including bipolar trans carotenoid salts (a subclass of TSC), have been studied by Diffusion Pharmaceuticals to treat conditions related to reduced oxygen availability in tissues (hypoxia).
Diffusion Pharmaceuticals product:The company’s main product candidate is sodium trans-crocetin, which has begun a phase III clinical trial for the treatment of glioblastoma multiforme (GBM); a phase II clinical trial for the treatment of pancreatic cancer; for the treatment of metastatic brain Phase II/III clinical trials for cancer; and Phase II clinical trials for the treatment of stroke.
The company is also developing a new PI3K/Akt/mTOR pathway inhibitor RES-529. The trial has completed two phase I clinical trials for the treatment of age-related macular degeneration; it is in the preclinical development stage, mainly for treatment Oncology GBM.